An Early Phase 1 interventional study of Scaling and root planing plus placebo and Photodynamic therapy (PDT) in Periodontal Disease, sponsored by University of Pristina. Completed. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-13.
Sponsored by University of Pristina · Early Phase 1, Interventional, and Treatment
Patients with moderate periodontal destruction underwent mechanical debridement of the pathological changes from the periodontal pockets in one of the randomly selected quadrants and in another, also randomly selected, quadrant. In addition to non-surgical debridement, photodynamic therapy was applied. This comparison between two treatment options was evaluated between subjects who smoke and non-smokers.
830 studies on the registry are indexed under Periodontal Diseases; 188 are open to participants now.
This study's enrollment of 120 is above the median of 45 across 530 interventional studies indexed under Periodontal Diseases.
Browse Periodontal Diseases studies →University of Pristina is the lead sponsor of 3 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Non-surgical treatment
Procedure: Scaling and root planing plus placebo
Application of photodynamic therapy as an adjunct to non-surgical therapy
Combination Product: Photodynamic therapy (PDT)
Non-surgical treatment of periodontal pockets
Also known as: scaling and root planning
Photodynamic therapy was applied to a previously treated pocket with non-surgical therapy
Periodontal pocket depth reduction
Time frame: 6 weeks
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Pristina